All News - Eli Lilly and Company
WEBRecent Press Releases. View All Press Releases. FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis. September 13, 2024. Lilly expands manufacturing footprint in Ireland with $1.8 billion investment.
Lilly.com | Eli Lilly and Company
WEBSep 13, 2024 — Press Releases. ALL CORPORATE FINANCIAL PRODUCT IMPACT ARCHIVE. New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis. September 25, 2024.
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEBSep 24, 2024 — "Lilly scientists have been dedicated to research in Alzheimer's disease for more than 35 years, and this news is testament to their ingenuity, perseverance, and commitment to helping people with this disease," said Ilya Yuffa, executive vice president and president of Lilly International, Eli Lilly and Company.
News Release - Eli Lilly and Company
WEBMay 24, 2024 — Since 2020, Lilly has committed more than $16 billion to develop new manufacturing sites in the U.S. and Europe. New locations outside Indiana include Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and …
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
WEBJun 11, 2024 — On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
Lilly.com | Eli Lilly and Company
WEBSep 4, 2024 — INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens. Antimicrobial resistance (AMR) is one of the top public.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 — Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 — Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
WEBJun 26, 2023 — Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.